Vivtex inks $2.1b Novo Nordisk collab for oral obesity drug
Novo Nordisk committed up to $2.1 billion for rights to Vivtex's oral drug-delivery platform. The collaboration aims to convert injectable peptide obesity and diabetes drugs into oral pills to improve adherence and broaden access.
Why it mattersNovo Nordisk's $2.1B deal to oralize peptide obesity drugs signals need to reassess manufacturing and regulatory strategies.
People Mentioned
Bob Langer